Standard BioTools' (LAB) shares were down about 9% in recent Thursday trading after KeyBanc downgraded the company's stock to sector weight from overweight.
The downgrade followed the company's "disappointing" full year 2025 guidance, Keybanc said in an earnings recap Wednesday.
The firm said Standard BioTools' 2025 revenue outlook of $165 million to $175 million fell short of the $186.9 million consensus estimate and KeyBanc's $185 million projection.
"The company attributed its guidance to the proposed White House [National Institutes of Health] spending cut that may drive cautious spending for its academic customers," KeyBanc said.
Trading volume stood at more than 3.6 million shares against a daily average of roughly 1.7 million.
Price: 1.07, Change: -0.11, Percent Change: -8.97
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。